Business
BillionToOne Provides Guidance for 2026
MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reiterated the full year 2025 guidance of $293 million to $299 million with positive GAAP operating income and initiated the full year 2026 guidance. Full Year 2026 Guidance Full year 2026 total revenue of $415 million to $430 million, representing growth of 40% to 45% compar
About this update from Billiontoone, Inc.
[{"type":"image","alt":"BillionToOne, Inc.","displaySize":"","headline":null,"caption":"BillionToOne, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":158,"url":"https://media.zenfs.com/en/globenewswire.com/a8773d444a4068c16414f95fd9063401"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rXKo9dBLUOvPQyzwoqhIZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a8773d444a4068c16414f95fd9063401","width":300,"height":158}},"lazy":false},{"type":"text","content":"MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reiterated the full year 2025 guidance of $293 million to $299 million with positive GAAP operating income and initiated the full year 2026 guidance.","length":373,"tagName":"p"},{"type":"text","content":"Full Year 2026 Guidance","length":23,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Full year 2026 total revenue of $415 million to $430 million, representing growth of 40% to 45% compared to the midpoint of the full year 2025 guidance range.","length":158,"tagName":"p"}]},{"val":[{"type":"text","content":"Positive GAAP operating income for the full year 2026.","length":54,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":212,"olType":false},{"type":"text","content":"“As we look ahead to 2026, we are excited by the opportunity to further scale our differentiated platform built on innovative science and disciplined execution,” said Dr. Oguzhan Atay, Co-founder and CEO of BillionToOne. “With a clear roadmap and focus on solving meaningful clinical challenges, we believe we are well positioned to deepen our impact on healthcare, while delivering a durable, high-quality growth profile this year.”","length":433,"tagName":"p"},{"type":"text","content":"About BillionToOne","length":18,"tagName":"p"},{"type":"text","content":"Headquartered in Menlo Park, California, BillionToOne is a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all. The company's patented Quantitative Counting Templates™ (QCT™) molecular counting platform is the only multiplex technology that can accurately count DNA molecules at ...